Detalhe da pesquisa
1.
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved].
NIHR Open Res
; 2: 49, 2023 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37035713